Applied DNA Sciences Inc (APDN)

[Shail]

Have been trying to pester Stony Brook with my mails. Their response below:

Can't extract much more out of them. I guess they are also bound by disclosure norms.


Shail

I know you wish the company well, and we appreciate your support, including your emails of concern, and even your criticisms. They are welcome.

The reality is, no one can accurately attribute share price movement within a given, in this case relatively short, period of time. You are asking for more than we know.

I do agree with you: we have publicized a great deal of positive news, and we have confidence that in the long run the market will value that accurately.

I think to be fair, we publish whatever news we can, as soon as we can within legal and compliance and sometimes contractual parameters, and that is not limited to the quarterly investor calls. For example, the results of the annual shareholders meeting can be found on our website, under Investor Information, at this URL:

http://www.adnas.com/annual-meeting-2014

The Proxy Statement detailing the capital restructuring plans are there in full public view as well.

I realize I have not answered all your questions. I can tell you that I will put your message in front of senior management, and your comments I'm sure will be seriously considered.

Mitchell





Mitchell Miller
Director, Communications
Applied DNA Sciences
50 Health Sciences Dr.
Stony Brook, NY 11790
www.adnas.com
917-573-3373

On Sep 19, 2014, at 3:25 PM,

Hi Mitchell,

How do you explain the consistent drop in price of the stock despite a number of positive announcements including those pertaining to the DLA and MDA.

At this rate, how does APDN management plan to handle the Reverse Split and uplist to a better exchange. There have been no reassuring words from the Dr. Or Karol to the shareholders. The only time we get to hear something from them is during the quarterly conference call and that too is always positive. Why then has the price per share been languishing in the 10 cent range.

There are other penny stocks which have far less going for them but show much better capital appreciation against any positive news. APDN share price movement on the other hand has been most disappointing over the last year or more.

After the last quarter, APDN was obviously facing a cash crunch. There has been no news on success with funding. What was the outcome of the recently held conference in New York. I feel that the shareholders need to be better informed on all fronts, in order for them to be able to make sound investment decisions.

Look forward to your reply.

Regards.

Shail

Sent from my iPad

On Sep 15, 2014, at 10:41 AM, Mitchell Miller <[e-mail]> wrote:

Shailesh, please be assured that we are concerned and are monitoring the share price, as well as the needs, and communications to our long-term investors all the time, every day, literally. Your questions and comments are more than welcome, and always taken with great consideration.

Mitchell

Mitchell Miller
Director, Communications
Applied DNA Sciences
50 Health Sciences Dr.
Stony Brook, NY 11790
www.adnas.com
917-573-3373

On Sep 15, 2014, at 11:20 AM,

Hello all,

Is anyone watching the stock price movement. Do you have a response to my earlier mail.

Would appreciate a reply.

Thanks and regards.

Shail

Sent from my iPad

On Sep 10, 2014, at 1:31

Hi Debbie,

What's happening with the stock price. At this rate, even a ratio of 1:60 will not be sufficient. I hope you guys are watching and are generally concerned about long term investors.

When will the RS be announced and what will be the ratio for the RS. Please clarify.

Thanks and regards.

Shail